Literature DB >> 26778713

Comparison of Renal Cell Carcinoma Surveillance Guidelines: Competing Trade-Offs.

Jennifer M Lobo1, Marc Nelson2, Naveen Nandanan3, Tracey L Krupski3.   

Abstract

PURPOSE: We estimated the differences in intensity, cost, radiation exposure and cancer control of published surveillance guidelines screening for secondary renal cell carcinoma in patients treated with partial nephrectomy.
MATERIALS AND METHODS: We developed a Monte Carlo simulation model to contrast the existing guidelines in terms of cost, radiation exposure and cancer control. Model inputs were extrapolated from the existing literature. Surveillance guidelines were analyzed from the AUA, CUA, EAU and NCCN®. Risk stratification among patients treated with partial nephrectomy was based on tumor characteristics.
RESULTS: Expected costs during the 5 years after partial nephrectomy were $587 (CUA), $1,076 (AUA), $1,705 (EAU) and $1,768 (NCCN) for low risk patients, and $903 (CUA), $2,525 (EAU) and $3,904 (AUA and NCCN) for high risk patients. Radiation exposure ranged from 31.41 mSv (CUA) to 104.34 mSv (NCCN) for low risk patients and 46.88 mSv (CUA) to 231.61 mSv (AUA and NCCN) for high risk patients. The EAU and CUA guidelines led to the diagnosis of the highest percentage of low risk patients (more than 95%) while all guidelines diagnosed more than 92% of high risk patients with recurrence.
CONCLUSIONS: Renal cell carcinoma surveillance guidelines differ greatly in terms of intensity, cost and radiation exposure. It is important for clinicians to adopt standardized surveillance strategies that limit unnecessary cost and radiation exposure without compromising cancer control.
Copyright © 2016 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  carcinoma, renal cell; computer simulation; diagnostic imaging; practice guidelines as topic; recurrence

Mesh:

Year:  2016        PMID: 26778713     DOI: 10.1016/j.juro.2015.12.094

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  4 in total

Review 1.  Kidney cancer: Recurrence in renal cell carcinoma: the work is not done.

Authors:  Maxine Sun; Toni K Choueiri
Journal:  Nat Rev Urol       Date:  2016-03-31       Impact factor: 14.432

Review 2.  Recurrence in Localized Renal Cell Carcinoma: a Systematic Review of Contemporary Data.

Authors:  Jacqueline M Speed; Quoc-Dien Trinh; Toni K Choueiri; Maxine Sun
Journal:  Curr Urol Rep       Date:  2017-02       Impact factor: 3.092

Review 3.  Follow-up after curative treatment of localised renal cell carcinoma.

Authors:  Saeed Dabestani; Lorenzo Marconi; Teele Kuusk; Axel Bex
Journal:  World J Urol       Date:  2018-05-16       Impact factor: 4.226

4.  Modification of American Joint Committee on cancer prognostic groups for renal cell carcinoma.

Authors:  Ning Shao; Hong-Kai Wang; Yao Zhu; Ding-Wei Ye
Journal:  Cancer Med       Date:  2018-10-10       Impact factor: 4.452

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.